Location History:
- Shanghai, CN (2020 - 2021)
- Hong Kong, CN (2021 - 2023)
Company Filing History:
6 out of 7 
3 out of 4 
2 out of 27,394 
Years Active: 2020-2025
Title: Yanfeng Li: Innovator in Chimeric Antigen Receptor Technology
Introduction
Yanfeng Li is a prominent inventor based in Hong Kong, China, known for his significant contributions to the field of biomedical engineering. He holds a total of 12 patents, showcasing his innovative spirit and dedication to advancing medical technology. His work primarily focuses on developing chimeric antigen receptors (CARs) that target specific cancer cells.
Latest Patents
One of Yanfeng Li's latest patents is titled "Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof." This invention provides a combined chimeric antigen receptor that includes a single-chain variable fragment (scFv) targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The invention also encompasses a nucleic acid molecule encoding the chimeric antigen receptor, a corresponding expression vector, and CAR-T cells. Experimental results indicate that this chimeric antigen receptor exhibits a high killing ability against tumor cells, making it a promising treatment for CD19 and/or CD20 positive B-cell lymphoma, leukemia, and other related diseases.
Career Highlights
Throughout his career, Yanfeng Li has worked with notable organizations, including Cellular Biomedicine Group HK Limited and Cellular Biomedicine Group, Inc. His experience in these companies has allowed him to collaborate with other experts in the field and contribute to groundbreaking research in cancer treatment.
Collaborations
Yanfeng Li has collaborated with esteemed colleagues such as Yutian Wei and Yihong Yao. These partnerships have further enhanced his research and development efforts in the field of chimeric antigen receptors.
Conclusion
Yanfeng Li's innovative work in developing chimeric antigen receptors has the potential to revolutionize cancer treatment. His contributions to the field are significant, and his patents reflect his commitment to advancing medical technology.